Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Probable serine protease inhibitor.. Zusätzlich bieten wir Ihnen Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Antikörper (43) und Serine Peptidase Inhibitor, Kazal Type 7 (Putative) Kits (12) und viele weitere Produktgruppen zu diesem Protein an.
Showing 7 out of 8 products:
n cultured keratinocytes, SPINK7 mRNA expression was up-regulated by IL-17A together with IFNgamma
Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2
ECRG2 in combination with cisplatin (DDP) can inhibit viability and induce apoptosis in esophageal cancer DDP-resistant cells, possibly via upregulation of p53 expression and downregulation of PCNA expression.
miR-1322 can regulate ECRG2 in an allele-specific manner and that serum levels of miR-1322 can serve as a potential diagnostic biomarker for patients with ESCC.
Conformational study of ECRG2 using NMR.
ECRG2 is a novel member of the Kazal-type serine protease inhibitor family and may function as a tumor suppressor gene regulating the protease cascades during carcinogenesis and invasion of esophageal cancer.
ECRG2 regulates invasion/migration partly through ECM degradation and uPA/uPAR/FPRL1 pathway
Data suggest that the physical interaction of esophageal cancer related gene 2 (ECRG2) and metallothionein 2A (MT2A) may play an important role in the carcinogenesis of esophageal cancer.
Potential interaction partner for ECRG2 might be involved in regulation of cell proliferation and apoptosis and in various physiological processes.
Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer
Short tandem repeat polymorphism TCA3/TCA3 in exon 4 of ECRG2 is associated with poor relapse-free survival in surgically completely resected oral squamous cell carcinoma patients and might be a potential prognostic marker
results suggest that ECRG2 inhibits aggressiveness of cancer cell, possibly through the down-regulation of uPA/plasmin activity
genetically fixed short tandem repeat polymorphism TCA3/TCA3 in exon 4 of ECRG2 is associated with poor clinical outcome in surgically treated esophageal cancer patients and might be a potential prognostic marker
ECRG2 is important for ensuring centrosome duplication, spindle assembly checkpoint, and accurate chromosome segregation, and its depletion may contribute to chromosome instability and aneuploidy in human cancers.
the ECRG2 TCA (3)/TCA (4) genotype is associated with the risk of oesophageal carcinoma in a North Indian population.
uPA-binding loops of ECRG2 are in correspondence with the reactive site loops for binding of serine proteinase in turkey ovomucoid third domain (OMTKY3).
ECRG2 is involved in the regulation of cell migration/invasion through uPA/uPAR/beta1 integrin pathway.
Probable serine protease inhibitor.
, esophagus cancer-related gene 2 protein
, esophagus cancer-related protein 2
, serine peptidase inhibitor, Kazal type 7 (putative)
, serine protease inhibitor Kazal-type 7
, allergen Gal d 1
, allergen Gal d I
, esophagus cancer related gene 2
, esophagus cancer-related gene-2